Genomewide cDNA microarray screening of genes related to benefits and toxicities of platinum-based chemotherapy in patients with advanced lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 367-370

  Oshita, Fumihiro ^a   Ikehara, Mizuki ^a   Sekiyama, Akiko ^a   Hamanaka, Nobuyuki ^a   Saito, Haruhiro ^a   Yamada, Kouzo ^a   Noda, Kazumasa ^a   Kameda, Yoichi ^a   Miyagi, Yohei ^a  

^a KANAGAWA CANCER CENTER   (Japan)

Author keywords

Cancer; Gene; Lung; Microarray

Indexed keywords

PLATINUM DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; INFECTION; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; NEUTROPENIA; PNEUMONIA; THROMBOCYTOPENIA; TRANSBRONCHIAL BIOPSY; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CREATININE; DIARRHEA; FEMALE; GENE EXPRESSION; GENETIC SCREENING; HUMANS; INFECTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPENIA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATINUM COMPOUNDS;

EID: 23244436358     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000158828.06866.ec     Document Type: Article

References (9)

1. Shinkai T, Eguchi K, Sasaki Y, et al. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol. 1992;30:1-6.
2. Oshita F, Ikehara M, Sekiyama A, et al. Genomic-wide cDNA microarray screening to correlate gene expression profile with chemoresistance in patients with advanced lung cancer. J Exp Ther Oncol. 2004;4:155-160.
3. Ikehara M, Oshita F, Sekiyama A, et al. Genomic-wide cDNA microarray screening to correlate gene expression profile with survival in patients with advanced lung cancer. Oncol Rep. 2004;11:1041-1044.
4. World Health Organization. WHO hand book for reporting results of cancer treatment. WHO offset publication no. 48. Geneva: World Health Organization; 1979.
5. National Cancer Institute. Common toxicity criteria. Version 2. Available at http://ctep.cancer.gov/reporting/CTC-3.html.
6. Chenchik A, Zhu YY, Diatchenko L, et al. Generation and use of high-quality cDNA from small amounts of total RNA by SMART PCR. In: Siebert PD, Larrick JW, eds. Gene cloning and analysis by RT-PCR. MA: Bio Techniques Book; 1998:305-319.
7. Garceau V, Houle MG, Chouinard F, et al. Characterization of cytohesin-1 monoclonal antibodies: expression in neutrophils and during granulocytic maturation of HL-60 cells. J Immunol Methods. 2001;249:121-136.
8. Kamens J, Paskind M, Hugunin M, et al. Identification and characterization of ICH-2, a novel member of the interleukin-1-converting enzyme family of cysteine proteases. J Biol Chem. 1995;270:15250-15256.
9. Das S, Ward SV, Markle D, et al. DNA damage-binding proteins and heterogeneous nuclear ribonucleoprotein A1 function as constitutive KCS element components of the interferon-inducible RNA-dependent protein kinase promoter. J Biol Chem. 2004;279:7313-7321.